Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT2 zipalertinib in EGFR-mutant advanced or metastatic NSCLC
jRCT2061230057Phase 2Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall response rate. Started Nov 2023; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230057.